Intelligent Bio Solutions Inc. (INBS) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2026, Intelligent Bio Solutions reported revenue of $4.2M, up 38.1% from $3.1M the year before. Net income was -$12.4M (a -294.9% net margin), or -$8.44 per diluted share. Gross margin was 48.6% and operating margin was -299.1%. Operating activities generated -$11.9M of cash, leaving -$12.1M of free cash flow. At fiscal year end, Intelligent Bio Solutions held $11.9M in total assets against $6.7M in total liabilities, including $4.0M of cash and equivalents.
Open the full interactive Intelligent Bio Solutions financials → Quarterly statements, key ratios, valuation history and price charts.
Intelligent Bio Solutions Key Stats
| Share Price | $1.48 |
|---|---|
| Market Cap | $2.2M |
| Revenue YoY Growth | +38.1% |
| 52-Week Range | $1.48 – $17.92 |
| Shares Outstanding | 1.5 million (basic, 2026 Q4) |
Intelligent Bio Solutions Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $437,146 | $1.3M | $3.1M | $3.1M | $4.2M |
| Gross Profit | — | — | $326,668 | $1.4M | $1.2M | $2.0M |
| Operating Income | -$5.6M | -$8.3M | -$12.6M | -$10.3M | -$10.6M | -$12.6M |
| Pre-Tax Income | -$7.1M | -$8.3M | -$10.6M | -$10.2M | -$10.6M | -$12.4M |
| Income Tax | -$22,915 | — | — | — | — | — |
| Net Income | -$7.0M | -$8.3M | -$10.6M | -$10.2M | -$10.6M | -$12.4M |
| Diluted EPS | -$1632.00 | — | -$1269.60 | -$63.80 | -$20.00 | -$8.44 |
Intelligent Bio Solutions Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $1.1M | $896,774 | $1.1M | $1.1M |
| Net Income | -$3.0M | -$2.7M | -$2.9M | -$3.9M |
| Diluted EPS | -$3.50 | -$2.82 | -$1.80 | -$2.65 |
Intelligent Bio Solutions Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.6M | $8.2M | $1.5M | $6.3M | $1.0M | $4.0M |
| Current Assets | $18.2M | $10.9M | $3.9M | $8.5M | $4.1M | $7.1M |
| Total Assets | $21.9M | $12.4M | $10.4M | $13.8M | $8.2M | $11.9M |
| Current Liabilities | $3.7M | $4.7M | $5.9M | $5.5M | $5.4M | $4.9M |
| Total Long-Term Debt | — | — | $756,073 | — | — | — |
| Total Liabilities | $6.9M | $5.8M | $6.7M | $5.6M | $5.4M | $6.7M |
| Shareholders' Equity | $15.1M | $6.6M | $3.8M | $8.3M | $3.0M | $5.5M |
Intelligent Bio Solutions Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$11.3M | -$3.4M | -$7.4M | -$9.6M | -$9.7M | -$11.9M |
| Cash From Investing | — | -$880,221 | -$694,142 | -$221,426 | -$231,838 | -$85,573 |
| Cash From Financing | $23.4M | — | $1.4M | $14.6M | $4.6M | $15.0M |
| Free Cash Flow | — | — | — | -$9.6M | -$9.9M | -$12.1M |
Figures from Intelligent Bio Solutions' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Intelligent Bio Solutions financials page for every line item.
Intelligent Bio Solutions Company Profile
| Ticker | INBS |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001725430 |
Frequently Asked Questions
What was Intelligent Bio Solutions' revenue in fiscal 2026?
Intelligent Bio Solutions (INBS) reported revenue of $4.2M for fiscal 2026.
What is Intelligent Bio Solutions' annual revenue history?
Intelligent Bio Solutions' annual revenue by fiscal year: 2021: $2.0M; 2022: $437,146; 2023: $1.3M; 2024: $3.1M; 2025: $3.1M; 2026: $4.2M.
What was Intelligent Bio Solutions' net income in fiscal 2026?
Intelligent Bio Solutions reported net income of -$12.4M for fiscal 2026.
What was Intelligent Bio Solutions' earnings per share (EPS) in fiscal 2026?
Intelligent Bio Solutions' diluted EPS was -$8.44 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Intelligent Bio Solutions generate in fiscal 2026?
Intelligent Bio Solutions generated -$12.1M of free cash flow in fiscal 2026.
What was Intelligent Bio Solutions' revenue last quarter?
In its most recent reported quarter (2026 Q4), Intelligent Bio Solutions reported revenue of $1.1M.
How many shares of Intelligent Bio Solutions are outstanding?
Intelligent Bio Solutions reported a weighted average of 1.5 million basic shares outstanding in 2026 Q4.
What is Intelligent Bio Solutions' market cap?
Based on its latest closing price, Intelligent Bio Solutions (INBS) has a market capitalization of about $2.2M.
When does Intelligent Bio Solutions' fiscal year end?
Intelligent Bio Solutions' fiscal year end, as registered with the SEC, is June 30.
Where is Intelligent Bio Solutions headquartered?
Intelligent Bio Solutions lists its business address in New York, New York in its SEC filings.
Intelligent Bio Solutions Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →